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Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA),
and it is generally accepted that these patients should receive low-intensity conditioning because of the
underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally
been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of
these patients. This retrospective analysis of 94 pediatric patients with FAwho underwent related HCT at King
Faisal Specialist Hospital & Research Center was carried out to attempt to identify factors that may affect
outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years,
respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was
associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respec-
tively; P ¼ .035), and use of radiation-containing regimens was associated with a signiﬁcantly lower 10-year
OS than nonradiation regimens (76% versus 91%, respectively; P ¼ .005). Of the 4 regimens used in this study,
the ﬂudarabine-based regimen was associated with the highest survival (95.2%; P ¼ .034). The use of the
higher dose CY (60 mg/kg) was associated with a signiﬁcantly increased incidence of hemorrhagic cystitis
(HC) (20% versus 5.6% respectively; P ¼ .049). Three patients (3%) developed squamous cell carcinoma
(2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-
containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg)
conditioning regimen may be associated with better survival, it is also associated with a signiﬁcantly
increased risk of HC. The addition of ﬂudarabine to the low-dose CY (20 mg/kg) is associated with the best
survival. On the other hand, radiation-containing regimens are associated with signiﬁcantly lower survival.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION or total body irradiation (TBI), and with or without antithy-
Fanconi anemia (FA) is a rare, genetically heterogeneous,
inherited disorder clinically characterized by congenital ab-
normalities, progressive bone marrow failure, and a pre-
disposition to develop malignancies [1-4], especially acute
myeloid leukemia and squamous cell carcinoma, mostly
head and neck [5-9]. Allogeneic hematopoietic cell trans-
plantation (HCT) currently remains the only curativemodality
for bone marrow failure in FA patients; HCT does not, how-
ever, prevent the occurrence of solid tumors [10]. The use of
conditioning regimens based on reduced doses of cyclo-
phosphamide (CY), either alone or together with limited ﬁelddgments on page 1602.
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14.06.016mocyte globulin (ATG), has resulted in restoration of normal
hematopoiesis in a large proportion of patients, particularly
those who underwent transplantation from HLA-matched
related donors [11-25].
Despite the favorable overall outcome in recipients of
HLA-matched related HCT, variations in the preparatory
regimens still exist among different institutions, as well as in
the reported outcomes (survival and pattern of toxicity), and
only few studies have investigated the factors that may affect
the eventual outcome of these patients. We analyzed data
from King Faisal Specialist Hospital & Research Center
(KFSH&RC) database to evaluate the impact of different key
variables on outcome of related HCT in pediatric FA patients.PATIENTS AND METHODS
Patients
A review of our data at KFSH&RC from 1993 to 2011 identiﬁed 94 FA
patients who underwent related bone marrow HCT. Forty-six (48.9%) wereTransplantation.
Table 2
Patients and Transplantation Characteristics
Factors n (%)
N 94
Age at HCT, yr 94
Mean, SD 8.73  .33
Median, range 8.53, 1.36-15.02
Age group
<10 yr 59 (62.8)











60 mg/kg 40 (42.6)







Use of XRT (TBI þ TAI)
No 60 (63.8)
Yes 34 (36.2)
XRT indicates radiation; SD, standard deviation.
Data presented are n (%) unless otherwise indicated.
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clone (MDS) in bone marrow before HCT, and 1 patient had acute myeloid
leukemia, received chemotherapy, and was in remission at time of HCT.
Conditioning Regimens
CY was used in the conditioning regimens in all patients; 1 of 2 doses of
CY was used according to the time period when the patient underwent HCT:
a higher dose, CY 60 mg/kg, used with ATG with no other agents (n¼ 40), or
a lower dose, CY 20mg/kg, used in combinationwith ATG and radiation (TBI,
n ¼ 11; or thoraco-abdominal irradiation [TAI], n ¼ 22), or used in combi-
nation with ATG and ﬂudarabine (n ¼ 21); 1 of the patients in the latter
group also received TBI. Graft-versus-host disease (GVHD) prophylaxis was
with cyclosporine. ATG was delivered after HCT to the 22 patients with CY/
TAI and to 20 patients who received the higher dose CY conditioning
regimen (Table 1).
Endpoints and Deﬁnitions
The primary outcome studied was survival. Patients were classiﬁed
according to the conditioning regimen received. Patients were considered to
have an event at time of death from any cause; survivors were censored at
last contact. Time to engraftment was calculated as the interval from trans-
plantation to the ﬁrst of 3 consecutive days with an absolute neutrophil
count (ANC) of 500/mm3. Primary graft failure was deﬁned as failure to
achieve an ANC of 500/mm3 after HCT, and secondary graft failure was
deﬁned as sustained loss of ANC (<500/mm3) after initial recovery. Acute
GVHD was graded using the International Bone Marrow Transplantation
Registry (IBMTR) Severity Index [26]. Chronic GVHD was diagnosed by
published criteria [27]. Death without the event was considered a
competing event for engraftment and GVHD. At KFSH&RC, pediatric patients
are patients whose age is 14 years.
Statistical Analyses
Overall survival (OS) probability was estimated using the Kaplan-Meier
method. Univariate analyses were conducted to evaluate the impact of key
variables on survival as well as on the incidence of graft failure, GVHD, and
hemorrhagic cystitis (HC). These variables include age at HCT (<10 years
versus 10 to 14 years), recipient or donor gender, presence of MDS before
HCT, use of ﬂudarabine in the conditioning regimen, dose of CY in the
conditioning regimen, and use of radiation in the conditioning regimen; the
small sample size precluded multivariate analysis. Survival curves were
drawn using Kaplan-Meier methodology and were compared using log-rank
and Tarone-ware tests wherever applicable. Chi-square and Fisher exact
tests were used to compare the signiﬁcance of independence between the
categorical variables. Cumulative incidence curves were tested using Fine
and Gray method. The statistical analyses were performed with SPSS 13.0
(SPSS Inc. Chicago, IL) and R (R Development Core Team 2009, Vienna,
Austria) software packages.
RESULTS
Patients and transplantation characteristics are summa-
rized in Table 2. The median CD34 dose was 5.62  106/kg
(range, 1.16 to 24.2  106/kg). Donor source was an HLA-
matched sibling in 86 patients, an HLA-matched parent in
3, and an HLA-class I single antigenemismatched sibling or
parent in 5. The median age of the donor was 13.14 years
(range, 1.36 to 45.2 years).
Engraftment, GVHD, HC, and Veno-Occlusive Disease of
the Liver
Engraftment occurred in all patients, at a median of 14
days (range, 9 to 33 days). Platelet-transfusion independenceTable 1
Details of the Conditioning Regimens
Conditioning Regimen Time Period when Regimen
Was Used
Patients, n
CY (20 mg/kg), ATG, TAI 1995-1999 22
CY (60 mg/kg), ATG 2000-2007 40
CY (20 mg/kg), ﬂu, ATG 2008-2011 21*
CY (20 mg/kg), ATG, TBI In patients with MDS,
regardless of time of HCT
11
Flu indicates ﬂudarabine.
* One patient in this group received TBI in addition to CY/ﬂu/ATG.occurred in 92 patients, at a median of 29 days (range, 14 to
97 days). The cumulative incidences of acute GVHD grade II
to IV and of grade III to IV were 8.5% (SE, 2.8%) and 5.3% (SE,
2.2%), respectively. Chronic GVHD (cGVHD) developed in 8 of
90 patients at risk (cumulative incidence, 8.5%; SE, 2.8%); 2
had limited disease and 6 had extensive disease. Six of those
who developed cGVHD were alive at the last follow-up.
Cumulative incidence of secondary graft failure was 4.3%
(SE, 2%) and for HC was 12.5% (SE, 3.2%). Mild self-limiting
veno-occlusive disease developed in 6 patients (6.4%).
Univariate analysis revealed that the incidence of acute
GVHD was not affected by age at HCT, gender of recipient
or donor, concomitant MDS, or use of higher-dose CY or
ﬂudarabine-based regimens. However, the incidence of acute
GVHD grade II to IV and grade III to VI was higher in patients
who received the TBI-containing regimen; 25% (SE, 13%)
versus 6% (SE, 2.6%) and 2.4% (SE, 1.4%) in those who did not
(P ¼ .02 and P ¼ .001, respectively). Similarly, cGVHD inci-
dence was 25% (SE, 13%) in recipients of the TBI-containing
conditioning regimen versus 6.1% (SE, 2.6%) in the other
group (P value ¼ .03). Also, the cumulative incidence of
secondary graft failure was higher in the TAI recipients
group: 13.6% (SE, 7.1%) compared with 1.4% (SE, 10%) in the
others (P ¼ .01). More cases of HC were noted in recipients of
the higher doses of CY (60 mg/kg), 20% versus 5.6% in all
others (P ¼ .049).Survival
Probabilities of OSwere 92.5%, 89%, and 86% at 1, 5, and 10
years, respectively (Figure 1). When OS was evaluated based
on the CY dose used, the 10-year OS was signiﬁcantly better
among recipients of the higher dose CY conditioning regimen
(91.4% versus 82%, P ¼ .035), and when OS was evaluated
based on the existence of radiation in the conditioning, OS
Figure 1. Overall survival of all patients.
Table 3
Univariate Analysis of Association of Prognostic Factors with Survival
Factors Overall Survival
Estimate  SEM P Value
Age group .616
<10 yr .827  .063
10 yr .911  .049
Gender (recipient) .723
Male .822  .078
Female .887  .048
Gender (donor) .896
Male .875  .048
Female .842  .075
Conditioning regimens .034
With TAI .724  .096
With TBI .818  .116
CY 60 mg/kg .914  .063
Flu-based .952  .046
Conditioning regimens .020
With XRT (TAI þ TBI) .755  .075
CY 60 mg/kg .914  .063
Flu-based .952  .046
CY dose .035
CY 60 mg/kg .914  .063
CY 20 mg/kg .822  .054
Use of TBI .573
No .867  .045
Yes .825  .113
Use of TAI .006
No .893  .055
Yes .724  .096
Use of XRT (TBI þ TAI) .005
No .906  .062
Yes .759  .074
Presence of MDS/leukemia before HCT .816
No .860  .045
Yes .889  .105
SEM indicates standard error of mean.
M. Ayas et al. / Biol Blood Marrow Transplant 20 (2014) 1599e1603 1601was signiﬁcantly higher among recipients of nonradiation-
containing conditioning regimens (90.6% versus 75.9%, P ¼
.005). Because CY 20mg/kgwas used inmore than 1 regimen,
we also evaluated survival according to the 4 regimens
(TAI-based, TBI-based, CY 60 mg/kg without radiation,
ﬂudarabine-based); OS was highest in the recipients of the
ﬂudarabine-based regimen (95.2%; P¼ .034) (Figure 2,
Table 3).
In univariate analysis, OS was not affected by any of the
following variables: age at HCT (<10 years versus 10 to 14
years), recipient or donor gender, or the presence of MDS
before HCT.
Secondary Malignancy
Six (6.4%) patients developed malignancies. Three (3.2%)
developed squamous cell carcinoma (2 oropharyngeal and 1
genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them
had radiation-containing conditioning. Three patients de-
veloped acute leukemia; 2 acute myeloid and 1 acute mixed
lineage, at 7.1, 2.7, and 2.2 years after HCT.
DISCUSSION
Low-dose CY has remained the backbone of the prepa-
ratory regimens used for FA patients undergoing allogeneicFigure 2. Overall survival according to the conditioning regimen.HCT since it was shown more than 3 decades ago to be
associated with increased survival [11,28]. Regimens have,
however, continued to evolve, and the “low” dose of CY has
subsequently varied from 1 study to another, depending on
what other agents were used concomitantly; doses as low as
20 mg/kg and up to 80 mg/kg have been used with favorable
outcomes, particularly in recipients of matched related HCT
[12,13,15-23].
The ﬁrst reports used a combination of CY (20 to 40 mg/
kg) with reduced-dose TAI or TBI (400 to 450 cGy), and
resulted in a long-term survival of 58.5% [13]. Later, the
addition of ATG to the same regimen seemed to improve
survival [16,19]. Higher doses of CY were used without ATG;
Zanis-neto conditioned 30 patients with CY (60 to 80mg/kg),
and 26 were alive at the time of the report [17]. The addition
of ﬂudarabine to the conditioning regimens of FA patients
undergoing unrelated donor and cord HCT improved out-
come [25,29,30], but its impact on the outcome of FA patients
undergoing matched related donor has, thus far, been less
clear. In this retrospective review, we corroborate that
related HCT for FA patients is associated with excellent long-
term survival, and we demonstrate that the higher dose CY
(60 mg/kg) in the conditioning is associated with signiﬁ-
cantly better survival and that radiation-containing regi-
mens are associated with signiﬁcantly inferior survival; but,
we also demonstrate that the addition of ﬂudarabine to the
low-dose CY in the last few years is associated with the
highest probability of survival in our patient cohort, in
keeping with the recently published European Society for
Blood and Marrow Transplantation experience [25].
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better outcome in FA patients [25,31], but in this report we
are not able to determine the impact of younger age at time
HCT because the age limit in this study was 14 years. How-
ever, a comparison between the 2 age groups (<10 years
versus 10 to 14 years) at the time of HCT did not show any
signiﬁcant difference in survival.
GVHD is a major cause of morbidity and mortality of HCT
and may be a predictor of head and neck malignancy in FA
patients [13,14,32]. The ﬁrst reports of low-dose CY/TAI in FA
patients showed a high incidence of acute and chronic GVHD
(55% and 70%) with only cyclosporine used for prophylaxis
[14]. The addition of ATG to the same regimenwas associated
with a lower incidence of GVHD [15,16]. Higher doses of CY in
the conditioning of FA patients have been associated with a
higher incidence of GVHD [17,33], presumably because of the
underlying defective DNA repair in FA cells [14,34]. Addi-
tional factors, such as the presence of extensive congenital
malformations, have been also described to affect the inci-
dence of GVHD and survival of FA patients [33,35]. In this
study, the overall incidence of GVHD was relatively low and
did not appeardon univariate analysisdto be associated
with age at HCT, gender of recipient or donor, use of ﬂudar-
abine in the conditioning, or dose of CY; only recipients of the
TBI regimen appeared to have a higher incidence. In patients
with hematological malignancies undergoing unrelated HCT,
the addition of ATG to the preparative regimens was shown
to decrease the incidence of chronic GVHD [36,37], so it is
conceivable that the use of ATG may have mitigated the
GVHD incidence and severity in our cohort.
HC may be an equally disturbing complication in FA
patients after HCT; in this study, more patients in the CY
60 mg/kg group developed HC: 20% versus 5.6% in the CY
20 mg/kg group (P ¼ .049). Interestingly, this did not seem to
be a salient complication in another large study that used CY
60 mg/kg, where only 1 of 23 patients had HC [17]. This may
be explained by the different complementation groups in the
2 patient populations but the data to conﬁrm this assump-
tion are not available.
Graft failure is associated with a dismal prognosis as
salvage options are limited; second transplantation may be
considered in these patients but extreme care must be
exercised as further cytotoxic conditioning may be detri-
mental [38]. The incidence of graft failure in FA patients
varies from 1 study to another; Socié et al. reported a total of
4 graft failures (8%), 3 primary and 1 secondary, in 49 pa-
tients who underwent matched related HCT after condi-
tioningwith CY 20mg/kg and TAI [13]. The addition of ATG in
the report by Farzin et al. resulted in a 7% incidence of graft
failure (1 primary and 1 secondary) [17]. In this study, we
report a relatively low incidence of secondary graft failure of
4.3%, and unlike the data of patients with acquired aplastic
anemia, where eliminating radiation increased the risk of
graft failure [39,40], we show here that graft failure occurred
in more patients who received the TAI regimen and that the
use of nonradiation regimens was associated with lower risk
of graft failure and better survival, conforming to previously
published data [31,41].
Despite the drawback of being a retrospective study, the
strength of our report lies in the fact that it is 1 of largest to
be reported from a single institution. Our data conﬁrm that
related HCT for pediatric FA patients is associated with
excellent long-term survival and suggest that radiation is
best avoided in their conditioning. Although our data suggest
that a higher dose CY conditioning regimen was associatedwith better survival, we believe that lower doses are rec-
ommended in view of the higher incidence of HC in the
higher dose CY patient cohort, and in light of the excellent
results in this study and other published studies with the
lower CY 20 mg/kg dose with ﬂudarabine [21-23]. Finally,
although this study suggests that, among younger patients
(ie, those 14 years who constitute the patient cohort in this
study), early transplantation (below 10 years) did not
improve survival, we continue to believe FA patients should
undergo HCT when they become blood productetransfusion
dependent, particularly if they have amatched related donor.
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